Lewy Body Disease (Lewy Body Dementia)

Subscribe to Selected New Research on Lewy Body Disease

301 relevant articles (11 outcomes, 27 trials/studies) found for this Disease

Description: A neurodegenerative disease characterized by dementia, mild parkinsonism, and fluctuations in attention and alertness. The neuropsychiatric manifestations tend to precede the onset of bradykinesia, MUSCLE RIGIDITY, and other extrapyramidal signs. DELUSIONS and visual HALLUCINATIONS are relatively frequent in this condition. Histologic examination reveals LEWY BODIES in the CEREBRAL CORTEX and BRAIN STEM. SENILE PLAQUES and other pathologic features characteristic of ALZHEIMER DISEASE may also be present. (From Neurology 1997;48:376-380; Neurology 1996;47:1113-1124)

Also Known As:

Lewy Body Dementia; Cortical Lewy Body Disease; Lewy Body Disease, Cortical; Lewy Body Disease, Diffuse; Lewy Body Type Senile Dementia; Dementia, Lewy Body; Diffuse Lewy Body Disease

Relationship Network

Disease Context: Research Results

Nervous System Diseases: 3414

Neurodegenerative Diseases: 7363

Lewy Body Disease: 301

Central Nervous System Diseases: 930

Movement Disorders: 1472

Parkinsonian Disorders: 4714

Lewy Body Disease: 301

Brain Diseases: 1120

Dementia: 10685

Lewy Body Disease: 301

Basal Ganglia Diseases: 181

Parkinsonian Disorders: 4714

Lewy Body Disease: 301

Mental Disorders: 1709

Cognitive Disorders Amnestic Dementia Delirium: 45

Dementia: 10685

Lewy Body Disease: 301

Related Diseases

1.	Alzheimer Disease (Alzheimer's Disease)
2.	Dementia (Dementias)
3.	Parkinson Disease (Parkinson's Disease)
4.	Vascular Dementia (Subcortical Arteriosclerotic Encephalopathy)
5.	Neurodegenerative Diseases (Neurodegenerative Disease)

Experts

1.	Takahashi, Hitoshi: 3 articles (11/2007 - 08/2003)
2.	Pettegrew, Jay W: 2 articles (06/2008 - 09/2006)
3.	Mandal, Pravat K: 2 articles (06/2008 - 09/2006)
4.	Iwatsubo, Takeshi: 2 articles (11/2007 - 08/2003)
5.	Padovani, Alessandro: 2 articles (12/2006 - 10/2004)
6.	Masliah, Eliezer: 2 articles (09/2006 - 01/2004)
7.	Mori, Fumiaki: 2 articles (06/2005 - 08/2003)
8.	Wakabayashi, Koichi: 2 articles (06/2005 - 08/2003)
9.	Dalfó, E: 2 articles (10/2004 - 06/2004)
10.	Ferrer, I: 2 articles (10/2004 - 06/2004)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Lewy Body Disease:

1.	rivastigmine (Exelon)FDA LinkGeneric 09/01/2003 - "Rivastigmine also was proven effective in decreasing psychiatric symptoms and cognitive deficits in a large double-blind, placebo-controlled trial in patients with diffuse Lewy body disease" 01/01/2002 - "Studies with the dual ChE inhibitor rivastigmine in mild to moderately severe AD and in Lewy body dementia (LBD) have shown improvements in behavioral symptoms including psychosis" 01/01/2005 - "The effect of rivastigmine is best documented in Lewy body dementia (LB)" 12/16/2000 - "INTERPRETATION: Rivastigmine 6-12 mg daily produces statistically and clinically significant behavioural effects in patients with Lewy-body dementia, and seems safe and well tolerated if titrated individually." 05/01/2007 - "Hallucinations associated to treatment with rivastigmine in two patients with diffuse Lewy body disease]" Order ALL the reference details at left...
2.	donepezil (Aricept)FDA Link 03/01/2005 - "This report discusses a case of an elderly woman with a diagnosis of probable Lewy body dementia who had significant improvement with donepezil but discontinued it due to side effects" 10/26/2004 - "Severe worsening of parkinsonism in Lewy body dementia due to donepezil." 11/25/2003 - "Severe worsening of parkinsonism in Lewy body dementia due to donepezil." 05/01/2007 - "Officially approved for mild-to-moderate and severe AD, donepezil has also been shown to be effective in early-stage AD, vascular dementia, Parkinson's disease dementia/Lewy body disease and cognitive symptoms associated with multiple sclerosis" 01/01/2006 - "Nine hundred and ninety-four AD patients received study drug, of whom 49 (4.9%) had symptoms suggestive of concomitant Lewy body disease (25 rivastigmine, 24 donepezil)" Order ALL the reference details at left...
3.	Levodopa (L Dopa)FDA LinkGeneric 05/01/2003 - "For patients with Lewy body dementia, levodopa often provides a significant improvement of the extrapyramidal syndrome in about 70p.cent of the treated patients" 03/01/2003 - "Levodopa improved rapid eye movement sleep behavior disorder with diffuse Lewy body disease." 07/01/1992 - "These cases emphasize that (1) Lewy body Parkinson's disease cannot be excluded on the basis of atypical presentation or levodopa nonresponsiveness, and (2) the clinicopathologic spectrum of Lewy body disease is varied." 05/01/1986 - "A common clinical manifestation of idiopathic Lewy body disease is levodopa responsive idiopathic Parkinson's disease" 09/01/1997 - "Fifty-three (16.6%) of 320 patients with levodopa-responsive parkinsonism (PD) had a history of HT; similar prevalence of presymptomatic HT was seen for PS and dementia (22/165 [13.3%]), including probable diffuse Lewy body disease and multiple system atrophy of the nigrostriatal degenerative type (33/171 [19.3%])" Order ALL the reference details at left...
4.	alpha-SynucleinIBA 06/01/2004 - "The present study examines alpha-synuclein interactions with rab3a and rabphilin by antibody arrays, immunoprecipitation and pull-down methods in the entorhinal cortex of control cases and in diffuse Lewy body disease (LBD) cases" 12/01/2000 - "In this study, we observed that AGEs and alpha-synuclein are similarly distributed in very early Lewy bodies in the human brain in cases with incidental Lewy body disease" 11/01/2008 - "2006) Phosphorylation of Ser-129 is the dominant pathological modification of alpha-synuclein in familial and sporadic Lewy body disease" 04/11/2008 - "In summary, Y39C human alpha-synuclein transgenic mice show age-dependent, progressive neuronal degeneration with motor and cognitive deficits similar to diffuse Lewy body disease" 12/01/2007 - "In many cases, however, Alzheimer pathology overlaps with Lewy body disease, characterized by the accumulation of a third cross-beta-sheet forming protein, alpha-synuclein" Order ALL the reference details at left...
5.	Cholinesterase Inhibitors (Anticholinesterases)IBA 10/01/2005 - "Larger scale, placebo controlled clinical trials are needed to provide an evidence base to guide the clinical use of cholinesterase inhibitors in Lewy body disease." 04/01/1996 - "In this article, Paolo Liberini and colleagues suggest that the cluster of responders to the cholinesterase inhibitors might include a significant number of subjects with a rather selective dysfunction of the cholinergic system, as in the case of Lewy-body dementia" 04/01/1996 - "Lewy-body dementia and responsiveness to cholinesterase inhibitors: a paradigm for heterogeneity of Alzheimer's disease?" 02/20/2002 - "There is currently no cure for dementia disorders, although acetylcholinesterase inhibitors may prove effective for Alzheimer's disease and Lewy body dementia" 04/01/2006 - "Establishing a diagnosis of dementia was considered important because Alzheimer's disease and Lewy body dementia can be treated with cholinesterase inhibitors" Order ALL the reference details at left...
6.	beta-SynucleinIBA 12/01/2004 - "An antiaggregation gene therapy strategy for Lewy body disease utilizing beta-synuclein lentivirus in a transgenic model." 04/01/2007 - "These results support the contention that in Parkinson's disease and Lewy body dementia, alpha-syn oligomers on the membrane might form pore-like structures, and that the beneficial effects of beta-synuclein might be related to its ability to block the formation of pore-like structures." 10/01/2006 - "Previous studies have shown that beta-synuclein (beta-syn), the homologue of alpha-syn, inhibited alpha-syn aggregation and stabilized Akt cell survival signaling molecule, suggesting that beta-syn was protective against alpha-syn-related neurodegenerative disorders, such as Parkinson's disease and diffuse Lewy body disease" Order ALL the reference details at left...
7.	1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)IBA 01/01/2007 - "RESULTS: Results demonstrated that ablation of EP2(EP2-/-) significantly enhanced microglia-mediated ex vivo clearance of alpha-synuclein aggregates (from mesocortex of Lewy body disease patients) while significantly attenuating neurotoxicity and extent of alpha-synuclein aggregation in mice treated with a parkinsonian toxicant 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine" 06/16/2006 - "We herein report that far upstream element-binding protein 1 accumulates in Parkin knock-out mice, patients with autosomal recessive juvenile parkinsonism, sporadic Parkinson disease, and diffuse Lewy Body disease as well as the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease" Order ALL the reference details at left...
8.	ButyrylcholinesteraseIBA 08/01/2005 - "In secondary subgroup analyses, AD patients who had genotypes that encoded for full expression of the butyrylcholinesterase enzyme (BuChE wt/wt; n = 226/340), who were < 75 years of age (n = 362/994) or who had symptoms suggestive of concomitant Lewy body disease (n = 49/994) showed significantly greater benefits from rivastigmine treatment" Order ALL the reference details at left...
9.	cysteine string proteinIBA 10/01/2006 - "Two missense mutations of beta-syn were identified in familial and sporadic diffuse Lewy body disease, and wild type beta-syn was induced to form fibril structures in vitro, while, alpha-syn was shown to be protective against neurodegeneration caused by deletion of cysteine-string protein-alpha, the presynaptic cochaperone to Hsc70 in mice" Order ALL the reference details at left...
10.	Codon (Codons)IBA 12/01/2003 - "The nitric oxide synthase-3 codon 298 polymorphism is not associated with late-onset sporadic Alzheimer's dementia and Lewy body disease in a sample from Hungary." 08/01/2004 - "The present study examines by immunohistochemistry Dpl expression in brain samples from 10 patients with Alzheimer's disease (AD), three patients with Pick's disease, four patients with Parkinson's disease, eight patients with diffuse Lewy body disease (DLBD), six patients with sporadic Creutzfeldt-Jakob disease (CJD) methionine/methionine at the codon 129, two patients with sporadic CJD methionine/valine at the codon 129 and numerous kuru plaques in the cerebellum, one patient with fatal familial insomnia (FFI), and 10 age-matched controls" 12/01/2003 - "An association study was performed between apolipoprotein E (apoE) polymorphism and the common structural polymorphism Glu/Asp at codon 298 of the nitric oxide synthase (NOS3) gene in late-onset sporadic Alzheimer's dementia probands (LOAD), diffuse Lewy body dementia cases (DLBD) and controls in a Hungarian sample" 11/01/2006 - "The present study examines, by gel electrophoresis and Western blotting, the expression levels of the water channels aquaporin 1 (AQP1) and aquaporin 4 (AQP4) in the frontal cortex (area 8) homogenates of sporadic CJD cases (six men, four women; seven cases with methionine/methionine at codon 129 and PrP type 1; two cases with valine/valine at codon 129 and PrP type 2, and one case methionine/valine at codon 129 and PrP type 1) compared with age-matched controls, and cases with Alzheimer's disease (AD, stage VI of Braak and Braak) and diffuse Lewy body disease (DLB)" Order ALL the reference details at left...

Therapies and Procedures

1.	Sympathectomy (Sympathectomies) 06/01/2005 - "Cardiac sympathetic denervation precedes neuronal loss in the sympathetic ganglia in Lewy body disease." 01/15/2006 - "BACKGROUND: Iodine-123-labeled metaiodobenzylguanidine (123I-MIBG) myocardial scintigraphy has been used to evaluate cardiac sympathetic denervation in Lewy body disease (LBD) including Parkinson's disease (PD) and dementia with Lewy bodies (DLB)" 01/01/2008 - "Not only TH- but also NF-immunoreactive (ir) axons in the epicardial nerve fascicles were markedly decreased in Lewy body disease, namely cardiac sympathetic denervation, which accounts for the reduced cardiac uptake of MIBG in Lewy body disease" 06/01/2005 - "Decreased cardiac uptake of MIBG in Lewy body disease reflects actual cardiac sympathetic denervation, which precedes the neuronal loss in the sympathetic ganglia." Order ALL the reference details at left...
2.	Therapeutics 11/01/2008 - "The diagnostic responsibility will increase with the development of new specific therapeutics and knowledge of contraindications such as the use of neuroleptics in patients suffering from Lewy body dementia" Order ALL the reference details at left...
3.	Parenteral Nutrition 09/01/2004 - "Special attention is paid to the distinctive clinical features, laboratory data and neuroimaging findings of frequent diseases as well as important ones including multiple system atrophy, progressive supranuclear palsy, corticobasal degeneration, Lewy body disease, drug-induced parkinsonism, vascular pseudo-parkinsonism, normal pressure hydrocephalus and manganese intoxication due to parenteral nutrition" Order ALL the reference details at left...
4.	Home Nursing (Nursing, Home) 12/01/2007 - "These cases included: a community-dwelling male in his early eighties with dementia who was found to have multiple cortical and striatal lacunes and glial scars, small vessel cerebrovascular disease (SVD) and AD-related pathology; a community-dwelling male in his mid-seventies with depression and loss of concentration, with brainstem predominant Lewy body disease (LBD) and AD-related pathology; and a female nursing home resident in her nineties with a history of stroke and prior suicide attempts who was found to have infarcts and SVD in frontal regions" Order ALL the reference details at left...
5.	Coronary Artery Bypass (Coronary Artery Bypass Surgery) 01/01/2007 - "The current paper provides an overview to guide accurate diagnosis, particularly in women, of different types of cognitive impairment under the broad category of dementias, including Alzheimer's, Lewy Body Disease, Vascular Dementia, and due to general medical conditions such as coronary artery bypass surgery, head injury, menopause, hypothyroidism, breast cancer treatment, Fibromyalgia, and chronic fatigue" Order ALL the reference details at left...

Best Treatments:
Research Summary Report
on Lewy Body Disease

*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 11 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>